News | October 16, 2007

Jury Renders Alleged Patent Infringement “Willful”

October 17, 2007 - After a three-week trial, a jury rendered a verdict of "willful" patent infringement in a dispute filed against CHF Technologies, Inc., d/b/a BioVentrix, after Chase Medical sued BioVentrix alleging its Blue Egg Sizer, a hollow, blue silicone device used to guide surgeons in surgically resizing the heart, infringed patents held by Chase.

Chase claimed the Blue Egg Sizer was similar to its balloon-like apparatus used in similar procedures.

Chase's case focused primarily on obsolete marketing material, website content that was retracted in early 2005 by BioVentrix, and an abandoned patent application.

Arthur Bertolero, Co-Founder of BioVentrix, said, “We were very careful of the plaintiff's intellectual property when we designed the Blue Egg. We looked at the limitations imposed by their device and produced something very different, a substantial improvement over the Chase device. We never intended to infringe and are concerned that the jury found an intentional breach. We are respectful of the importance and sovereignty of the patent process, and are disappointed with the verdict."

As for what BioVentrix will do in case of an unfavorable ruling, Kenneth Miller, President and CEO of BioVentrix, stated, "We recognize the authority of the Federal Court and the jury system, and will abide by the Judge’s final ruling, but remain confident that we will ultimately prevail.”

For more information: www.BioVentrix.com

Related Content

Bilateral Artery Use Does Not Improve 10-Year CABG Outcomes
News | Cardiovascular Surgery | September 06, 2018
While it is firmly established that the use of one internal thoracic artery can improve life expectancy in coronary...
Mandatory Public Coronary Artery Bypass Grafting Reporting Associated With Better Patient Outcomes
News | Cardiovascular Surgery | April 30, 2018
Mandatory public reporting of coronary artery bypass grafting (CABG) results in Massachusetts was associated with...
Gecko Biomedical Receives CE Mark Approval for Setalum Sealant
News | Cardiovascular Surgery | September 19, 2017
Gecko Biomedical announced it has received CE Mark approval for its Setalum Sealant, allowing the company to market its...
ClearFlow Inc. Announces Positive U.S. Clinical Trial Results
News | Cardiovascular Surgery | September 08, 2017
September 8, 2017 — ClearFlow Inc.
Videos | Cardiovascular Surgery | July 19, 2017
This video educational session, provided in partnership with the American Society of Echocardiography (ASE), is title
Intensive Glycemic Control Program Produces Significant Per-Patient Cost Savings for CABG Surgery
News | Cardiovascular Surgery | May 25, 2017
A new study from Emory University observed a near-20 percent reduction in perioperative complications, a 1.2-day...
Risk of Heart Transplant Rejection Reduced by Desensitizing Patient Antibodies
News | Cardiovascular Surgery | May 23, 2017
The risk of heart transplant rejection can be reduced by desensitizing patient antibodies, according to research...
Scientists Show How Cells React to Injury From Open-Heart Surgery
News | Cardiovascular Surgery | May 04, 2017
Cedars-Sinai Heart Institute investigators have learned how cardiac muscle cells react to a certain type of injury that...
ERACS Session Highlights Need for Standardized Best Practices in Cardiac Surgery
News | Cardiovascular Surgery | May 02, 2017
The recently formed group Enhanced Recovery After Cardiac Surgery (ERACS) hosted an organizing session in Boston on...
ClearFlow Receives Frost & Sullivan New Product Innovation Award for PleuraFlow Technology
News | Cardiovascular Surgery | May 01, 2017
ClearFlow Inc. has received the prestigious 2017 Global Frost & Sullivan Award for New Product Innovation. The...
Overlay Init